About every fourth member of the cystic fibrosis (CF) community feels they’re not provided clear information about cross infection…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
People with cystic fibrosis (CF) who carry two disease-causing F508del mutations and those who have had no prior treatment…
Younger adults with cystic fibrosis (CF) and a history of frequent pulmonary exacerbations are more likely than other adult…
Treatment with the antibiotic azithromycin reduces abnormal thickening of the walls of bronchi — air passages leading to the…
Treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor), sold as Trikafta in the U.S., may save people with cystic…
Highly effective CFTR modulators, which target the cause of cystic fibrosis (CF), may ease signs of low iron levels…
Abnormal glucose tolerance is common in young cystic fibrosis (CF) patients. Early screening, starting at the age of 5,…
The Cystic Fibrosis Foundation (CFF) has invested another $5 million into BiomX, which will help fund a Phase…
Sotagliflozin, an oral medication approved in the U.S. under the brand name Inpefa as a broadly used treatment for…
Some people with cystic fibrosis (CF) have levels of sweat chloride above the cut-off for a diagnosis of the…